Maternal thrombophilia and adverse pregnancy outcomes

References

• Kupferminc MJ. Thrombophilia and preeclampsia: the evidence so far. Clin. Obstet. Gynecol.48, 406–415 (2005).
   PubMedGoogle Scholar
• Romero R, Dekker G, Kupferminc M et al. Can heparin prevent adverse pregnancy outcome? J. Matern. Fetal Neonatal Med.12, 1–8 (2002).
   PubMedGoogle Scholar
• Kupferminc MJ, Fait G, Many A, Gordon D, Eldor A, Lessing JB. Severe preeclampsia and high frequency of genetic thrombophilic mutations. Obstet. Gynecol.96, 45–49 (2000).
   PubMed Web of Science ®Google Scholar
• Dizon-Townson DS, Nelson LM, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am. J. Obstet. Gynecol.175, 902–905 (1996).
   PubMed Web of Science ®Google Scholar
• Weiner-Megnagi Z, Ben-Shlomo I, Goldberg Y, Shalev E. Resistance to activated protein C and the Leiden mutation: high prevalence in patients with abruptio placentae.Am. J. Obstet. Gynecol.179, 1565–1567 (1998).
   PubMedGoogle Scholar
• Peeters LLH. Thrombophilia and fetal growth restriction. Eur. J. Obstet. Gynecol. Reprod.Biol.95, 202–205 (2001).
   PubMedGoogle Scholar
• Verspyck E, Borg JY, Le Cam-Duchez V et al. Thrombophilia and fetal growth restriction. Eur. J. Obstet. Gynecol. Reprod. Biol.113, 36–40 (2004).
   PubMed Web of Science ®Google Scholar
• Preston FE, Rosendaal FR, Walker ID et al. Increased fetal loss in women with heritable thrombophilia. Lancet348, 913–916 (1996).
   PubMed Web of Science ®Google Scholar
• Dudding TE, Attia J. The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: a meta-analysis. Thromb. Haemost.91, 700–711 (2004).
   PubMed Web of Science ®Google Scholar
• Vossen CY, Preston FE, Conard J et al. Hereditary thrombophilia and fetal loss: a prospective follow-up study. Thromb. Haemost.2, 592–596 (2004).
   Google Scholar
• Sheiner E, Levy A, Katz M, Mazor M. Pregnancy outcome following recurrent spontaneous abortions. Eur. J. Obstet. Gynecol. Reprod. Biol.118(1), 61–65 (2005).
   PubMed Web of Science ®Google Scholar
• Rai R, Shelbak A, Cohen H et al. Factor V Leiden and acquired protein C resistance among 1000 women with recurrent miscarriage. Hum. Reprod.16, 961–965 (2001).
   PubMed Web of Science ®Google Scholar
• Raziel A, Kornberg Y, Friedler S, Schachter M, Sela BA, Ron-El R. Hypercoagulable thrombophilic defects and hyperhomocysteinemia in patients with recurrent pregnancy loss. Am. J. Reprod. Immunol.46, 65–71 (2001).
   Google Scholar
• Livingston JC, Barton JR, Park V, Haddad B, Phillips O, Sibai BM. Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia. Am. J. Obstet. Gynecol.185, 153–157 (2001).
   PubMed Web of Science ®Google Scholar
• Infante-Rivard C, Rivard GE, Yotov WV et al. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. N. Engl. J. Med.347, 19–25 (2002).
   PubMed Web of Science ®Google Scholar
• McCowan LM, Craigie S, Taylor RS, Ward C, McLintock C, North RA. Inherited thrombophilias are not increased in ‘idiopathic’ small-for-gestational-age pregnancies. Am. J. Obstet. Gynecol.188, 981–985 (2003).
   PubMed Web of Science ®Google Scholar
• Alfirevic Z, Mousa HA, Martlew V, Briscoe L, Perez-Casal M, Toh CH. Postnatal screening for thrombophilia in women with severe pregnancy complications. Obstet. Gynecol.97, 753–759 (2001).
   PubMed Web of Science ®Google Scholar
• Rasmussen A, Ravn P. High frequency of congenital thrombophilia in women with pathological pregnancies? Acta Obstet. Gynecol. Scand.83, 808–817 (2004).
   PubMed Web of Science ®Google Scholar
• Isermann B, Sood R, Pawlinski R et al. The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat. Med.9, 331–337 (2003).
   PubMed Web of Science ®Google Scholar
• Lay AJ, Liang Z, Rosen ED, Castellino FJ. Mice with a severe deficiency in protein C display prothrombotic and proinflammatory phenotypes and compromised maternal reproductive capabilities. J. Clin. Invest.115, 1552–1561 (2005).
   PubMedGoogle Scholar
• Sood R, Kalloway S, Mast AE, Hillard CJ, Weiler H. Fetomaternal cross talk in the placental vascular bed: control of coagulation by trophoblast cells. Blood107, 3173–3180 (2006).
   PubMed Web of Science ®Google Scholar
• Eldor A. Thrombophilia, thrombosis and pregnancy. Thromb. Haemost.86, 104–111 (2001).
   PubMed Web of Science ®Google Scholar
• Kupferminc MJ, Eldor A, Steinman N et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N. Engl. J. Med.340, 9–13 (1999).
   PubMed Web of Science ®Google Scholar
• Many A, Schreiber L, Rosner S, Lessing JB, Eldor A, Kupferminc MJ. Pathologic features of the placenta in women with severe pregnancy complications and thrombophilia. Obstet. Gynecol.98, 1041–1044 (2001).
   PubMed Web of Science ®Google Scholar
• Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur. J. Obstet. Gynecol. Reprod. Biol.101, 6–14 (2002).
   PubMed Web of Science ®Google Scholar
• Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet361, 901–908 (2003).
   PubMed Web of Science ®Google Scholar
• Lockwood CJ. Inherited thrombophilias in pregnant patients: detection and treatment paradigm. Obstet. Gynecol.99, 333–341 (2002).
   PubMed Web of Science ®Google Scholar
• Weintraub AY, Sheiner E, Levy A, Yerushalmi R, Mazor M. Pregnancy complications in women with inherited thrombophilia. Arch. Gynecol. Obstet.274, 125–129 (2006).
   PubMedGoogle Scholar
• Wu O, Robertson L, Twaddle S et al. Screening for thrombophilia in high-risk situations: systematic review and cost–effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol. Assess.10, 1–110 (2006).
   PubMed Web of Science ®Google Scholar
• Weintraub AY, Sheiner E, Bashiri A, Shoham-Vardi I, Mazor M. Is there a higher prevalence of pregnancy complications in a live-birth preceding the appearance of recurrent abortions? Arch. Gynecol. Obstet.271, 350–354 (2005).
   PubMedGoogle Scholar
• Dekker GA, de Vries JI, Doelitzsch PM et al. Underlying disorders associated with severe early-onset preeclampsia. Am. J. Obstet. Gynecol.173, 1042–1048 (1995).
   PubMed Web of Science ®Google Scholar
• Kupferminc MJ. Thrombophilia and pregnancy. Reprod. Biol. Endocrinol.1, 111 (2003).
   PubMedGoogle Scholar
• Lin J, August P. Genetic thrombophilias and preeclampsia: a meta-analysis. Obstet. Gynecol.105, 182–192 (2005).
   PubMed Web of Science ®Google Scholar
• Mello G, Parretti E, Marozio L et al. Thrombophilia is significantly associated with severe preeclampsia: results of a large-scale, case–controlled study. Hypertension46, 1270–1274 (2005).
   PubMed Web of Science ®Google Scholar
• de Vries JI, Dekker GA, Huijgens PC, Jakobs C, Blomberg BM, van Geijn HP. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies. Br. J. Obstet. Gynaecol.104, 1248–1254 (1997).
   PubMedGoogle Scholar
• Kupferminc MJ, Many A, Bar-Am A, Lessing JB, Ascher-Landsberg J. Mid-trimester severe intrauterine growth restriction is associated with a high prevalence of thrombophilia. Br. J. Obstet. Gynaecol.109, 1373–1376 (2002).
   Google Scholar
• Martinelli P, Grandone E, Colaizzo D et al. Familial thrombophilia and the occurrence of fetal growth restriction. Haematologica86, 428–431 (2001).
   PubMedGoogle Scholar
• Grandone E, Margaglione M, Colaizzo D et al. Lower birth-weight in neonates of mothers carrying factor V G1691A and factor II A(20210) mutations. Haematologica87, 177–181 (2002).
   PubMed Web of Science ®Google Scholar
• Kupferminc MJ, Peri H, Zwang E, Yaron Y, Wolman I, Eldor A. High prevalence of the prothrombin gene mutation in women with intrauterine growth retardation, abruptio placentae and second trimester loss. Acta Obstet. Gynecol. Scand.79, 963–967 (2000).
   PubMed Web of Science ®Google Scholar
• Vollset SE, Refsum H, Irgens LM et al. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine study. Am. J. Clin. Nutr.71, 962–968 (2000).
   PubMed Web of Science ®Google Scholar
• Franchi F, Cetin I, Todros T et al. Intrauterine growth restriction and genetic predisposition to thrombophilia. Haematologica89, 444–449 (2004).
   PubMedGoogle Scholar
• Howley HE, Walker M, Rodger MA. A systematic review of the association between factor V Leiden or prothrombin gene variant and intrauterine growth restriction. Am. J. Obstet. Gynecol.192, 694–708 (2005).
   PubMed Web of Science ®Google Scholar
• Robertson L, Wu O, Langhorne P et al. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thrombophilia in pregnancy: a systematic review. Br. J. Haematol.132, 171–196 (2006).
   PubMed Web of Science ®Google Scholar
• Goddijn-Wessel TA, Wouters MG, van de Molen EF et al. Hyperhomocysteinemia: a risk factor for placental abruption or infarction. Eur. J. Obstet. Gynecol. Reprod. Biol.66, 23–29 (1996).
   PubMed Web of Science ®Google Scholar
• van der Molen EF, Verbruggen B, Novakova I, Eskes TK, Monnens LA, Blom HJ. Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathy. Br. J. Obstet. Gynaecol.107, 785–791 (2000).
   Google Scholar
• Facchinetti F, Marozio L, Grandone E, Pizzi C, Volpe A, Benedetto C. Thrombophilic mutations are a main risk factor for placental abruption. Haematologica88, 785–758 (2003).
   PubMed Web of Science ®Google Scholar
• De Santis M, Cavaliere AF, Straface G, Di Gianantonio E, Caruso A. Inherited and acquired thrombophilia: pregnancy outcome and treatment. Reprod. Toxicol.22, 227–233 (2006).
   PubMed Web of Science ®Google Scholar
• Greer IA. Thrombophilia: implications for pregnancy outcome. Thromb. Res.109, 73–81 (2003).
   PubMed Web of Science ®Google Scholar
• Gris JC, Lissalde-Lavigne G, Quere I, Dauzat M, Mares P. Prophylaxis and treatment of thrombophilia in pregnancy. Curr. Opin. Hematol.13, 376–81 (2006).
   PubMed Web of Science ®Google Scholar
• Lissalde-Lavigne G, Fabbro-Peray P, Cochery-Nouvellon E et al. Factor V Leiden and prothrombin G20210A polymorphisms as risk factors for miscarriage during a first intended pregnancy: the matched case–control ‘NOHA first’ study. Thromb. Haemost.3, 2178–2184 (2005).
   Google Scholar
• Zammiti W, Mtiraoui N, Mercier E et al. Association of factor V gene polymorphisms (Leiden; Cambridge; Hong Kong and HR2 haplotype) with recurrent idiopathic pregnancy loss in Tunisia. A case–control study. Thromb. Haemost.95, 612–617 (2006).
   PubMed Web of Science ®Google Scholar
• Regan L, Rai R. Thrombophilia and pregnancy loss. J. Reprod. Immunol.55, 163–180 (2002).
   PubMed Web of Science ®Google Scholar
• Tulppala M, Viinikka L, Ylikorkala O. Thromboxane dominance and prostacyclin deficiency in habitual abortion. Lancet337, 879–881 (1991).
   PubMed Web of Science ®Google Scholar
• Preston FE, Rosendaal FR, Walker ID et al. Increased fetal loss in women with heritable thrombophilia. Lancet348, 913–916 (1996).
   PubMed Web of Science ®Google Scholar
• Sottilotta G, Oriana V, Latella C et al. Genetic prothrombotic risk factors in women with unexplained pregnancy loss. Thromb. Res.117, 681–684 (2006).
   PubMed Web of Science ®Google Scholar
• Onderoglu L, Baykal C, Al RA, Demirtas E, Deren O, Gurgey A. High frequency of thrombophilic disorders in women with recurrent fetal miscarriage. Clin. Exp. Obstet. Gynecol.33, 50–54 (2006).
   PubMedGoogle Scholar
• Kujovich JL. Thrombophilia and pregnancy complications. Am. J. Obstet. Gynecol.191, 412–424 (2004).
   PubMed Web of Science ®Google Scholar
• Many A, Elad R, Yaron Y, Eldor A, Lessing JB, Kupferminc MJ. Third-trimester unexplained intrauterine fetal death is associated with inherited thrombophilia. Obstet. Gynecol.99, 684–687 (2002).
   PubMed Web of Science ®Google Scholar
• Alonso A, Soto I, Urgelles MF, Corte JR, Rodriguez MJ, Pinto CR. Acquired and inherited thrombophilia in women with unexplained fetal losses. Am. J. Obstet. Gynecol.187, 1337–1342 (2002).
   PubMed Web of Science ®Google Scholar
• Triplett DA, Harris EN. Antiphospholipid antibodies and reproduction. Am. J. Reprod. Immunol.21, 123–131 (1989).
   PubMed Web of Science ®Google Scholar
• Rai RS, Clifford K, Cohen H, Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum. Reprod.10, 3301–3304 (1995).
   PubMed Web of Science ®Google Scholar
• Vincent T, Rai R, Regan L, Cohen H. Increased thrombin generation in women with recurrent miscarriage. Lancet352, 116 (1998).
   PubMed Web of Science ®Google Scholar
• Kovalevsky G, Gracia CR, Berlin JA, Sammel MD, Barnhart KT. Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis. Arch. Intern. Med.164, 558–563 (2004).
   PubMed Web of Science ®Google Scholar
• Krabbendam I, Franx A, Bots ML, Fijnheer R, Bruinse HW. Thrombophilias and recurrent pregnancy loss: a critical appraisal of the literature. Eur. J. Obstet. Gynecol. Reprod. Biol.118, 143–153 (2005).
   PubMed Web of Science ®Google Scholar
• Royal College of Obstretricians and Gynaecologists (RCOG). Clinical Green Top Guidelines, Guideline 37: Thromboprophylaxis During Pregnancy, Labour and After Vaginal Delivery. Royal College of Obstetricians and Gynaecologists. London, UK (2004).
   Google Scholar
• Gerhardt A, Scharf RE, Beckmann MW et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N. Engl. J. Med.342, 374–380 (2000).
   PubMed Web of Science ®Google Scholar
• Martinelli I, De Stefano V, Taioli E, Paciaroni K, Rossi E, Mannucci PM. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb. Haemost.87, 791–795 (2002).
   PubMed Web of Science ®Google Scholar
• Pabinger I, Grafenhofer H, Kyrle PA et al. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood100, 1060–1062 (2002).
   PubMed Web of Science ®Google Scholar
• Ginsberg JS, Brill-Edwards P, Burrows RF et al. Venous thrombosis during pregnancy: leg and trimester of presentation. Thromb. Haemost.67, 519–520 (1992).
   PubMed Web of Science ®Google Scholar
• Greer I, Hunt BJ. Low molecular weight heparin in pregnancy: current issues. Br. J. Haematol.128, 593–601 (2005).
   PubMed Web of Science ®Google Scholar
• Bates SM. Treatment and prophylaxis of venous thromboembolism during pregnancy. Thromb. Res.108, 97–106 (2002).
   PubMedGoogle Scholar
• Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest26, 627S–644S (2004).
   Google Scholar
• Lepercq J, Conard J, Borel-Derlon A et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. Br. J. Obstet. Gynaecol.108, 1134–1140 (2001).
   Google Scholar
• Dolovich L, Ginsberg JS, Douketis JD et al. A meta-analysis comparing low molecular weight heparins to unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch. Intern. Med.160, 181–188 (2000).
   PubMed Web of Science ®Google Scholar
• Gould MK, Dembitzer AD, Doyle RL et al. Low molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials. Ann. Intern. Med.130, 800–809 (1999).
   PubMed Web of Science ®Google Scholar
• Kupferminc MJ, Fait G, Many A et al. Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens. Pregnancy20, 35–44 (2001).
   PubMed Web of Science ®Google Scholar
• Brenner B, Bar J, Ellis M, Yarom I, Yohai D, Samueloff A; LIVE–ENOX Investigators. Effects of enoxaparin on late pregnancy complications and neonatal outcome in women with recurrent pregnancy loss and thrombophilia: results from the Live–Enox study. Fertil. Steril.84, 770–773 (2005).
   PubMed Web of Science ®Google Scholar
• De Carolis S, Ferrazzani S, De Stefano V et al. Inherited thrombophilia: treatment during pregnancy. Fetal Diagn. Ther.21, 281–286 (2006).
   PubMed Web of Science ®Google Scholar
• Brenner B, Hoffman R, Carp H, Dulitsky M, Younis J; Live–Enox Investigators. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the Live–Enox study. Thromb. Haemost.3, 227–229 (2005).
   Google Scholar
• Grandone E, Brancaccio V, Colaizzo D et al. Preventing adverse obstetric outcomes in women with genetic thrombophilia. Fertil. Steril.78, 371–375 (2002).
   PubMed Web of Science ®Google Scholar
• Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. Thromb. Haemost.1, 433–438 (2003).
   Google Scholar
• Gris JC, Mercier E, Quere I et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood103, 3695–3699 (2004).
   PubMed Web of Science ®Google Scholar
• Chasen ST. Peripartum and perioperative management of the anticoagulated patient. Obstet. Gynecol. Clin. North Am.33, 493–497 (2006).
   PubMedGoogle Scholar
• Sanson BJ, Lensing AW, Prins MH et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb. Haemost.81, 668–672 (1999).
   PubMed Web of Science ®Google Scholar
• Collaborative Low-dose Aspirin Study in Pregnancy Collaborative Group. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP Collaborative Group. Lancet343, 619–629 (1994).
   PubMed Web of Science ®Google Scholar
• ECPPA (Estudo Colaborativo para Prevencao da Pre-eclampsia com Aspirina) Collaborative Group. ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women. Br. J. Obstet. Gynaecol.103, 39–47 (1996).
   PubMedGoogle Scholar
• Rotchell YE, Cruickshank JK, Gay MP et al. Barbados Low dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. Br. J. Obstet. Gynaecol.105, 286–292 (1998).
   PubMedGoogle Scholar
• Vainio M, Kujansuu E, Iso-Mustajarvi M, Maenpaa J. Low dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. Br. J. Obstet. Gynaecol.109, 161–167 (2002).
   Google Scholar
• Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br. Med. J.314, 253–257 (1997).
   PubMed Web of Science ®Google Scholar
• Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am. J. Obstet. Gynecol.174, 1584–1589 (1996).
   PubMed Web of Science ®Google Scholar
• Dargaud Y, Rugeri L, Ninet J, Negrier C, Trzeciak MC. Management of pregnant women with increased risk of venous thrombosis. Int. J. Gynaecol. Obstet.90, 203–207 (2005).
   PubMed Web of Science ®Google Scholar
• Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum.42, 1309–1311 (1999).
   PubMed Web of Science ®Google Scholar
• Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N. Engl. J. Med.332, 993–997 (1995).
   PubMed Web of Science ®Google Scholar
• Shehata HA, Nelson-Piercy C, Khamashta MA. Management of pregnancy in antiphospholipid syndrome. Rheum. Dis. Clin. North Am.27, 643–659 (2001).
   PubMedGoogle Scholar
• Dentali F, Crowther M. Acquired thrombophilia during pregnancy. Obstet. Gynecol. Clin. North Am.33, 375–388 (2006).
   PubMed Web of Science ®Google Scholar
• Bulletti C, Flamigni C, Giacomucci E. Reproductive failure due to spontaneous abortion and recurrent miscarriage. Hum. Reprod. Update2, 118–136 (1996).
   PubMed Web of Science ®Google Scholar
• Lyden TW, Vogt E, Ng AK, Johnson PM, Rote NS. Monoclonal antiphospholipid antibody reactivity against human placental trophoblast. J. Reprod. Immunol.22, 1–14 (1992).
   PubMed Web of Science ®Google Scholar
• Adler RR, Ng AK, Rote NS. Monoclonal antiphosphatidylserine antibody inhibits intercellular fusion of the choriocarcinoma line, JAR. Biol. Reprod.53, 905–910 (1995).
   PubMed Web of Science ®Google Scholar
• Di Simone N, De Carolis S, Lanzone A, Ronsisvalle E, Giannice R, Caruso A. In vitro effect of antiphospholipid antibody-containing sera on basal and gonadotrophin releasing hormone-dependent human chorionic gonadotrophin release by cultured trophoblast cells. Placenta16, 75–83 (1995).
   PubMedGoogle Scholar
• Di Simone N, Ferrazzani S, Castellani R, De Carolis S, Mancuso S, Caruso A. Heparin and low-dose aspirin restore placental human chorionic gonadotrophin secretion abolished by antiphospholipid antibody-containing sera. Hum. Reprod.12, 2061–2065 (1997).
   PubMed Web of Science ®Google Scholar
• Hills FA, Abrahams VM, Gonzalez-Timon B et al. Heparin prevents programmed cell death in human trophoblast. Mol. Hum. Reprod.12, 237–243 (2006).
   PubMedGoogle Scholar
• Goel N, Tuli A, Choudhry R. The role of aspirin versus aspirin and heparin in cases of recurrent abortions with raised anticardiolipin antibodies. Med. Sci. Monit.12, 132–136 (2006).
   Google Scholar
• Krikun G, Lockwood CJ, Wu XX et al. The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: immunolocalization and in vitro regulation. Placenta15, 601–612 (1994).
   PubMedGoogle Scholar
• Rand JH, Wu XX, Guller S et al. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. Am. J. Obstet. Gynecol.171, 1566–1572 (1994).
   PubMed Web of Science ®Google Scholar
• Pierangeli SS, Vega-Ostertag M, Liu X, Girardi G. Complement activation: a novel pathogenic mechanism in the antiphospholipid syndrome. Ann. NY Acad. Sci.1051, 413–420 (2005).
   PubMedGoogle Scholar
• Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet. Gynecol.100, 408–413 (2002).
   PubMed Web of Science ®Google Scholar
• Noble LS, Kutteh WH, Lashey N, Franklin RD, Herrada J. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil. Steril.83, 684–690 (2005).
   PubMed Web of Science ®Google Scholar
• Stephenson MD, Ballem PJ, Tsang P et al. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin.J. Obstet. Gynaecol. Can.26, 729–734 (2004).
   PubMedGoogle Scholar
• Lepercq J, Conard J, Borel-Derlon A et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. Br. J. Obstet. Gynaecol.108, 1134–1140 (2001).
   Google Scholar
• Walenga JM, Jeske WP, Prechel MM, Bacher P, Bakhos M. Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugs. Semin. Thromb. Hemost.30(Suppl. 1), 69–80 (2004).
   PubMedGoogle Scholar
• Wawrzynska L, Tomkowski WZ, Przedlacki J, Hajduk B, Torbicki A. Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol. Haemost. Thromb.33, 64–67 (2003).
   PubMed Web of Science ®Google Scholar
• Pattison NS, Chamley LW, Birdsall M, Zanderigo AM, Liddell HS, McDougall J. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am. J. Obstet. Gynecol.183, 1008–1012 (2000).
   PubMed Web of Science ®Google Scholar